[1] |
SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun.
Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
|
[2] |
WEI Zhenzhen, SUI Hua, JIANG Yulang, SUN Mingyu, YAN Huaru, WANG Ziyuan.
Research on the molecular mechanism of Zuo Jin Wan combined with cetuximab inducing ferroptosis in KRAS mutant colorectal cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 130-137.
|
[3] |
ZHOU Guangchen, LIU Yixi, ZHENG Yun.
Colorectal cancer and microRNA: research progress
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
|
[4] |
LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui.
circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.
|
[5] |
CHEN Wenjie, WANG Yabing, CHEN Xiaolin, REN Junling, ZHAO Wanjun, CHEN bin.
Advances in the study of iodine-resistant differentiated thyroid cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 116-120.
|
[6] |
LU Qiong, ZHU Haihong, QI Tingting, LI Guohua, TENG Xinqi, QU Qiang, QU Jian.
OCTN2 gene polymorphisms affect the chemotherapeutic sensitivity of oxaliplatin in colorectal cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 401-407.
|
[7] |
ZHANG Dezhi, LIU Meng, ZHU Shaogong, LIU Guiju, JI Jie.
Efficacy and safety of XELOX therapy in comparison with capecitabine monotherapy in adjuvant chemotherapy for elderly patients with colorectal cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 926-936.
|
[8] |
WANG Ziyuan, SUN Mingyu.
Advances in research on long non-coding RNA in drug resistance of colorectal cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 796-802.
|
[9] |
SHI Lili, LIU Xingan, SHAN Guoyong.
Efficacy and safety of apatinib in the further line treatment for patients with advanced colorectal cancer failed after standard therapy and the preliminary analysis of efficacy predictors
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1388-1394.
|
[10] |
LI Rongzhen, MEI Jiazhuan, XIA Yunzhan, JI Jie.
Prognostic factors and safety study of R0 resection colorectal cancer patients received capecitabine based adjuvant chemotherapy in real world
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 704-711.
|
[11] |
QIAO Dawei, LI Yufang, XIAO Yun, JIANG Lishuang, BO Ping.
Research progress of Scutellaria barbata against colorectal cancer and its metastasis mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 332-336.
|
[12] |
BAI Yan, ZHENG Xiaoyong, YANG Yage, FANG Lifeng.
Influence of programmed death-ligand 1 genetic variation on the clinical outcomes of postoperative CRC patients received 5-FU based adjuvant chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 180-187.
|
[13] |
LI Xiaojie,ZHANG Shengwei,WANG Huasheng,WANG Dong, MEI Jiazhuan, DENG Yewei.
Effects of polymorphism of vascular endothelial growth factor A on the prognosis of colorectal cancer patients received fluorouracil based adjuvant chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 900-904.
|
[14] |
TAO Huai, XU Lujiadai, CHEN Xia.
Occurrence and clinical treatment of epilepsy associated with gene mutation in voltagegated sodium channel subtypes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 570-577.
|
[15] |
HU Yang, LI Zhixing, WANG Guo, ZHU Yuanshan.
Research progress of lncRNA and chemotherapy resistance in colorectal cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 456-463.
|